The United States Patent and Trademark Office (USPTO) has granted patent US12582688B2 for a topical composition designed to treat hypopigmentation. The patent, assigned to the University of Pretoria, claims a composition comprising a specific concentration of an ethanolic extract from the plant Aspalathus linearis, combined with a dermatologically acceptable carrier. This composition is intended for use in methods of preventing or treating hypopigmentary disorders of the skin by topical application.

This patent grant signifies a new intellectual property right for the University of Pretoria concerning a specific dermatological treatment. While this is a patent grant and not a regulatory rule imposing obligations on other entities, it is relevant for pharmaceutical and biotechnology companies operating in the dermatology and cosmetic sectors. Companies developing or marketing treatments for skin pigmentation disorders should be aware of this granted patent to ensure their products do not infringe upon the claims, particularly concerning the use of Aspalathus linearis extracts in topical formulations.